Provided by Tiger Trade Technology Pte. Ltd.

GRAYBUG VISION, INC.

5.50
0.0000
Volume:- -
Turnover:135.26K
Market Cap:8.64M
PE:-0.24
High:5.50
Open:5.50
Low:5.50
Close:5.50
52wk High:22.12
52wk Low:5.00
Shares:1.57M
Float Shares:737.07K
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-23.2400
EPS(LYR):-23.1962
ROE:-70.51%
ROA:-38.18%
PB:0.24
PE(LYR):-0.24

Loading ...

Company Profile

Company Name:
GRAYBUG VISION, INC.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.